NovoCure (NVCR) shares were down over 3% in recent Friday trading after Wells Fargo downgraded the stock to equal-weight from overweight and slashed its price target to $14.50 from $40.
Separately, Wedbush also cut its price target to $18 from $27.
Trading volume stood at over 2.8 million shares against a daily average of around 1.3 million.
Price: 12.11, Change: -0.43, Percent Change: -3.42
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。